Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum AstraZeneca ADR Representing 0.5 Ord Shs AZN

AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

NDAQ:AZN - Post Discussion

AstraZeneca ADR Representing 0.5 Ord Shs > AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
View:
Post by whytestocks on Feb 08, 2024 8:30pm

AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript

Breaking News: $AZN AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript2024-02-08 16:15:30 ET Image source: The Motley Fool. AstraZeneca Plc (NASDAQ: AZN) Q4 2023 Earnings Call Feb 08, 2024 , 6:45 a.m. ET Andy Barnett Continue reading For further details see: AstraZeneca Plc (AZN) Q4 2023 Earnings Call TranscriptAZN - AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities